Net Income

Affluent buyers in Southeast Asia are trading property for lifestyle, fueling a 230% boom in branded residences. Why is experience the new ultimate luxury?

A breakthrough clinical trial and a savvy financial move could net Fractyl Health $18M to advance its novel obesity treatment beyond the GLP-1 boom.

A decade-long wait ends as the FDA approves a new 1st-line therapy for HER2+ breast cancer. See how ENHERTU reshapes patient outcomes and market dynamics.

Biotech Immunome plans a massive stock offering. A deep dive into the high-stakes bet on its cancer pipeline and what it means for investors.

Boise Cascade's acquisition of Holden Humphrey aims to reshape the Northeast building materials market, consolidating its power and expanding its product lines.

IO Biotech’s cancer vaccine posts impressive 5-year survival data, but a narrow miss in its pivotal trial creates an uncertain path in a competitive market.

Beyond a routine board re-election, Heidmar Maritime is doubling down on an AI-driven strategy to navigate the volatile tanker market. Here's what it means.

Kodiak Sciences is raising crucial capital with a stock offering, diluting investors but fueling its late-stage retinal drugs. Is this a necessary lifeline or a red flag?

A modest dividend payout belies a massive ambition. Canterbury Park is betting its future not on the track, but on building an entire community around it.

Verastem Oncology taps industry heavyweights for its leadership, signaling a bold new strategy to accelerate its cancer pipeline and grow its market share.

Tiziana's CEO doubles down with a major share purchase, signaling deep faith in a novel MS drug, even as market signals send mixed messages.

A new report forecasts modest 2.6% growth for US construction in 2026, driven by data centers, water, and aviation, but challenged by major hurdles.

A new partnership claims to power an AI with meditated 'love' from at-risk communities. Is this a bold new paradigm or a controversial social experiment?

Voxel's AI transforms cameras into proactive safety systems, slashing injuries by 91% and proving that workplace safety is a powerful form of preventative care.

A sustainable energy firm's bold move into digital assets signals a new era of institutional crypto adoption, driven by South Korean demand for Ripple.

Quebec food distributor Colabor Group fails to secure a financial lifeline, risking creditor protection and threatening a major regional supply chain disruption.

Anixa Biosciences now fully controls its breast cancer vaccine after promising Phase 1 data. What does this strategic move mean for investors and medicine?

An Indiana biotech prepares for biotech's biggest stage, showcasing a pipeline that offers new hope for chronic endocrine and metabolic disorders.

Rail Vision just secured a key European patent for its AI collision avoidance tech. Is this IP fortress enough to challenge giants and define the future of rail?

After a NYSE delisting, FOXO Technologies is betting big on healthcare acquisitions. Is this a savvy turnaround or a high-risk gamble for investors?